Find a study
Match me to a study284 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Asthma
π Allervie Clinical Research Β· Birmingham, AL Β· +25 more US sites Β· Get directions β
This study tests how well different doses of povorcitinib work and whether it is safe for people with asthma that is not well controlled. People must have moderate to severe asthma despite using inhaled steroid and a long-acting beta-agonist (ICS-LABA) for at least 12 months.
- Type 2 diabetes
π Helios Clinical Research - Phoenix Β· Phoenix, AZ Β· +24 more US sites Β· Get directions β
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
- Kidney disease
π N America Res Inst - San Dimas Β· San Dimas, CA Β· +17 more US sites Β· Get directions β
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity.
- Depression
π Site 200 Β· Phoenix, AZ Β· +39 more US sites Β· Get directions β
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
- Obesity / overweight
π Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC Β· Gilbert, AZ Β· +25 more US sites Β· Get directions β
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
- Obesity / overweight
π University of Colorado School of Medicine Β· Aurora, CO Β· +1 more US site Β· Get directions β
Dr. Nanette Santoro proposes to test the specific question that obesity results in abnormal estradiol response at the level of the pituitary and hypothalamus.
- Kidney disease
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
π Emory Clinic Β· Atlanta, GA Β· +1 more US site Β· Get directions β
The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).
- Obesity / overweight
π The Institute for Liver Health II dba Arizona Clinical Trials - Mesa Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs.
- Obesity / overweight
π Arizona Clinical Trials-Chandler Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).
- Obesity / overweight
π The Institute for Liver Health II dba Arizona Clinical Trials - Mesa Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
- Type 2 diabetes
π Arizona Clinical Trials - Pecos Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol.
- Kidney disease
π Apogee Clinical Research, LLC Β· Huntsville, AL Β· +39 more US sites Β· Get directions β
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.
- Type 2 diabetes
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
π΅ May compensateπ Central Research Associates - Flourish - PPDS Β· Birmingham, AL Β· +30 more US sites Β· Get directions β
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers.
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health Β· Chandler, AZ Β· +39 more US sites Β· Get directions β
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.
- Kidney disease
π Research Site Β· Decatur, AL Β· +39 more US sites Β· Get directions β
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
- High blood pressureKidney disease
π Research Site Β· Surprise, AZ Β· +17 more US sites Β· Get directions β
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
- Heart / cardiovascular disease
π Nephrology of North Alabama Β· Decatur, AL Β· +39 more US sites Β· Get directions β
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Depression
π Noble Clinical Research Β· Tucson, AZ Β· +33 more US sites Β· Get directions β
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
- COPD (chronic lung disease)
π Research Site Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- COPD (chronic lung disease)
π SEC Clinical Research, LLC Β· Dothan, AL Β· +39 more US sites Β· Get directions β
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
- COPD (chronic lung disease)
π University of Alabama at Birmingham Hospital Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
- COPD (chronic lung disease)
π University of Alabama at Birmingham Lung Health Center Β· Birmingham, AL Β· +39 more US sites Β· Get directions β
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.
- COPD (chronic lung disease)
π University of Alabama at Birmingham Lung Health Center Β· Birmingham, AL Β· +21 more US sites Β· Get directions β
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
- Asthma
π Kymera Investigative Site Β· Lancaster, CA Β· +26 more US sites Β· Get directions β
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
- Asthma
π Hospital BritΓ‘nico de Buenos Aires_Site n. 032029 Β· Buenos Aires, Β· Get directions β
This study will compare an asthma inhaler that uses a new climate friendly alternative propellant to an asthma inhaler with an existing propellant. We want to make sure both versions of the inhaler work the same way for people with mild to moderate asthma.
- Asthma
π AMR Clinical Β· Tempe, AZ Β· +16 more US sites Β· Get directions β
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
- Asthma
π Research Site Β· Bakersfield, CA Β· +39 more US sites Β· Get directions β
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
- Asthma
π Velocity Clinical Research, Mobile Β· Mobile, AL Β· +35 more US sites Β· Get directions β
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected.
- Kidney disease
π Research Institute-McGill University Health Center Β· Montreal, Quebec Β· Get directions β
This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD. The primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test.
- Depression
π Seaport Investigator Site Β· Chino, CA Β· +27 more US sites Β· Get directions β
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
- Depression
π Site 7074 Β· Birmingham, AL Β· +37 more US sites Β· Get directions β
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
- Depression
π Alabama CRS Β· Birmingham, AL Β· +24 more US sites Β· Get directions β
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes.
- Depression
π Draig Clinical Site Β· Bentonville, AR Β· +22 more US sites Β· Get directions β
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo.
- Anxiety
π University of Alabama - Huntsville Regional Medical Campus /ID# 267818 Β· Huntsville, AL Β· +39 more US sites Β· Get directions β
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.
- Anxiety
π Clinical Site Β· Birmingham, AL Β· +29 more US sites Β· Get directions β
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
- Anxiety
π Clinical Site Β· Chandler, AZ Β· +33 more US sites Β· Get directions β
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
- Asthma
π Research Site Β· Bakersfield, CA Β· +10 more US sites Β· Get directions β
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
- Fatty liver disease (NASH/MASH)
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
π΅ May compensateπ Arizona Liver Health - Chandler Β· Chandler, AZ Β· +34 more US sites Β· Get directions β
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
- Depression
π University of Alabama at Birmingham Β· Birmingham, AL Β· +33 more US sites Β· Get directions β
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel.
- Depression
π Harmonex /ID# 277517 Β· Dothan, AL Β· +32 more US sites Β· Get directions β
Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains.
- Depression
π NoesisPharma, LLC Β· Phoenix, AZ Β· +31 more US sites Β· Get directions β
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel.
- Fatty liver disease (NASH/MASH)
π Arizona Liver Health - Chandler Β· Chandler, AZ Β· +30 more US sites Β· Get directions β
Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse
- Kidney disease
π R1 Therapeutics Clinical Trial Site Β· Huntsville, AL Β· +22 more US sites Β· Get directions β
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
- Anxiety
π SOAR Clinical Study Site Β· Pheonix, AZ Β· +10 more US sites Β· Get directions β
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD). The main questions this trial aims to answer are: * Is NTX-1472 safe and well tolerated in adults with SAD?
- Depression
π Site 6036 Β· Chandler, AZ Β· +26 more US sites Β· Get directions β
The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.
- Type 2 diabetes
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
π΅ May compensateπ Alliance Clinical Canoga Park (Hope Clinical Research) Β· Canoga Park, CA Β· +24 more US sites Β· Get directions β
Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin.
- Obesity / overweight
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
π΅ May compensateπ Arizona Clinical Trials Β· Chandler, AZ Β· +22 more US sites Β· Get directions β
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
- Obesity / overweight
π Kailera Clinical Site Β· Chandler, AZ Β· +22 more US sites Β· Get directions β
The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Efficacy in participants with type 2 diabetes mellitus will be evaluated.
- COPD (chronic lung disease)
π University of Alabama Β· Birmingham, AL Β· +22 more US sites Β· Get directions β
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
- Asthma
π Novartis Investigative Site Β· Rousse, Β· Get directions β
The purpose of this study is to characterize the bronchodilator effect, systemic exposure and safety/tolerability of two different doses of inhaled glycopyrronium, when compared to placebo. Outcome of this study will be used to determine the dose of inhaled glycopyrronium for the development of fixed dose combination indacaterol/mometasone/glycopyrronium (QVM149) for children aged 6 to less than 12 years old with moderate to severe asthma.
- Obesity / overweightType 2 diabetes
π Clinical Trial Site Β· Montclair, CA Β· +6 more US sites Β· Get directions β
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
- Anxiety
π Lighthouse Psychiatry Β· Gilbert, AZ Β· +21 more US sites Β· Get directions β
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
- Type 2 diabetes
π Lynn Institute of the Ozarks Β· Little Rock, AR Β· +8 more US sites Β· Get directions β
This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks.
- Depression
π University of Alabama at Birmingham Β· Birmingham, AL Β· +20 more US sites Β· Get directions β
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
- Obesity / overweight
π Children's Hospital Los Angeles Β· Los Angeles, CA Β· +19 more US sites Β· Get directions β
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL.
- Kidney disease
π University of California, Los Angeles Β· Los Angeles, CA Β· +17 more US sites Β· Get directions β
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo.
- Kidney disease
π Clinical Trial Site Β· San Francisco, CA Β· +3 more US sites Β· Get directions β
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
- Type 2 diabetes
π Central Research Associates, LLC dba Flourish Research Β· Birmingham, AL Β· +16 more US sites Β· Get directions β
This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.
- Fatty liver disease (NASH/MASH)
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
π΅ May compensateπ University of California San Diego Β· La Jolla, CA Β· +15 more US sites Β· Get directions β
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.
- Showing the first 60 of 284. Add filters or a location to narrow down.